SABSW Projected Dividend Yield
Wt Pur Com 10/22/2026/SAB Biotherapeutics Inc ( NASDAQ : SABSW )SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing fully human, multi-targeted, high-potency immunoglobulins (IgGs) without human donors or convalescent plasma to treat and prevent immune and autoimmune disorders. Its lead asset, SAB-142, targets type 1 diabetes with a disease-modifying approach. Using advanced genetic engineering, the company developed Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, enabling the DiversitAb system to produce diverse, high-potency, fully-human IgGs for various unmet medical needs. 21 YEAR PERFORMANCE RESULTS |
SABSW Dividend History Detail SABSW Dividend News SABSW Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |